Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ewa Olech

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Seminars in Arthritis and Rheumatism|March 8, 2016
Biosimilars: Rationale and current regulatory landscapeEwa Olech
Cleveland Clinic Journal of Medicine|December 1, 2005
DHEA supplementation: the claims in perspectiveEwa Olech, Joan T Merrill
Expert Review of Clinical Immunology|May 19, 2010
Mycophenolate mofetil for lupus nephritisEwa Olech, Joan T Merrill
Current Rheumatology Reports|January 28, 2009
Antiphospholipid antibodies in rheumatoid arthritis: identifying the dominoesDebbie A Gladd, Ewa Olech
Current Rheumatology Reports|March 30, 2006
The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritisEwa Olech, Joan T Merrill
Rheumatic Diseases Clinics of North America|July 24, 2012
Magnetic resonance imaging applications in early rheumatoid arthritis diagnosis and managementOrrin M Troum, Olga Pimienta, Ewa Olech
The Journal of Rheumatology|December 4, 2009
Bone marrow edema is the most specific finding for rheumatoid arthritis (RA) on noncontrast magnetic resonance imaging of the hands and wrists: a comparison of patients with RA and healthy controlsEwa Olech, John V Crues, David E Yocum, et al.
Seminars in Arthritis and Rheumatism|March 8, 2016
Development of biosimilarsAhmad Al-Sabbagh, Ewa Olech, Joseph E McClellan, et al.
The Journal of Rheumatology|April 3, 2013
Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label studyWilliam F C Rigby, Philip J Mease, Ewa Olech, et al.
Arthritis Research & Therapy|November 3, 2023
Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trialsJohn Tesser, Ahmet Gül, Ewa Olech, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Seminars in Arthritis and Rheumatism|March 8, 2016
Biosimilars: Rationale and current regulatory landscapeEwa Olech
Cleveland Clinic Journal of Medicine|December 1, 2005
DHEA supplementation: the claims in perspectiveEwa Olech, Joan T Merrill
Expert Review of Clinical Immunology|May 19, 2010
Mycophenolate mofetil for lupus nephritisEwa Olech, Joan T Merrill
Current Rheumatology Reports|January 28, 2009
Antiphospholipid antibodies in rheumatoid arthritis: identifying the dominoesDebbie A Gladd, Ewa Olech
Current Rheumatology Reports|March 30, 2006
The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritisEwa Olech, Joan T Merrill
Rheumatic Diseases Clinics of North America|July 24, 2012
Magnetic resonance imaging applications in early rheumatoid arthritis diagnosis and managementOrrin M Troum, Olga Pimienta, Ewa Olech
The Journal of Rheumatology|December 4, 2009
Bone marrow edema is the most specific finding for rheumatoid arthritis (RA) on noncontrast magnetic resonance imaging of the hands and wrists: a comparison of patients with RA and healthy controlsEwa Olech, John V Crues, David E Yocum, et al.
Seminars in Arthritis and Rheumatism|March 8, 2016
Development of biosimilarsAhmad Al-Sabbagh, Ewa Olech, Joseph E McClellan, et al.
The Journal of Rheumatology|April 3, 2013
Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label studyWilliam F C Rigby, Philip J Mease, Ewa Olech, et al.
Arthritis Research & Therapy|November 3, 2023
Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trialsJohn Tesser, Ahmet Gül, Ewa Olech, et al.
Pageof 3